Spyre Therapeutics Prices $403M Public Offering

Biotech firm raises funds for inflammatory bowel disease research

Apr. 15, 2026 at 2:39am

Got story updates? Submit your updates here. ›

An extreme close-up of heavy, textured metal gears and machinery in shades of silver, steel, and black, conceptually representing the complex financial infrastructure and institutional power behind a major biotech public offering.The intricate financial machinery behind Spyre Therapeutics' $403 million public offering signals the company's ambitions to advance its pipeline of innovative treatments for inflammatory bowel disease.Waltham Today

Spyre Therapeutics, a clinical-stage biotech company focused on inflammatory bowel disease and other immune-mediated diseases, announced the pricing of a $403 million public offering of 6.5 million shares of common stock at $62 per share. The company also granted underwriters a 30-day option to purchase up to an additional $60.5 million in shares.

Why it matters

The successful pricing of this upsized public offering provides Spyre Therapeutics with significant capital to advance its pipeline of investigational antibody therapies targeting inflammatory bowel disease and other immune disorders. As a clinical-stage biotech, securing this level of funding is crucial for the company to continue its research and development efforts.

The details

Spyre Therapeutics' pipeline includes extended half-life antibodies targeting a4p7, TL1A, and IL-23, which are key pathways involved in inflammatory bowel diseases like Crohn's and ulcerative colitis. The company aims to combine its antibody engineering expertise with dose optimization and rational therapeutic combinations to develop best-in-class treatments.

  • The offering is expected to close on or about April 16, 2026.
  • The underwriters have a 30-day option to purchase additional shares.

The players

Spyre Therapeutics

A clinical-stage biotechnology company advancing antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of inflammatory bowel disease and other immune-mediated diseases.

Jefferies LLC

One of the joint book-running managers for the public offering.

Goldman Sachs & Co. LLC

One of the joint book-running managers for the public offering.

Evercore ISI

One of the joint book-running managers for the public offering.

Guggenheim Securities, LLC

One of the joint book-running managers for the public offering.

Got photos? Submit your photos here. ›

What’s next

The offering is expected to close on or about April 16, 2026, subject to satisfaction of customary closing conditions.

The takeaway

Spyre Therapeutics' successful $403 million public offering demonstrates investor confidence in the company's innovative approach to developing next-generation treatments for inflammatory bowel disease and other immune-mediated disorders.